Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C

Hepatitis C Articles (HCV)


Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C

	Reported by Jules Levin 2017 APASL, Shanghai Sam Lee, Ph.D.

View Older Articles

Back to Top

www.natap.org